On the public citation graph
Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta‐Analysis
Inferred edges come from two machine sources: sweeps of open repository
metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is
labelled with the one it came from. Neither is a complete citation index — absence here is not
evidence of absence.
1 of the 26 references listed on this page is in the Retraction Watch database as retracted (export 2026-11-18): 10.1001/jamaoncol.2018.4070 (notice 2019-04-25).
Dataset join, best-effort; this page does not check the publisher record.
Retraction Watch data via Crossref Labs, used with credit; OpenCitations Index (CC0) and Meta (CC BY 4.0);
dataset doi:10.7910/DVN/WT8VOA (CC BY 4.0).
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated
CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/hep.28280openalex-snapshotAntiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta‐analysis
inferredcites →https://doi.org/10.1007/s10620-017-4448-7openalex-snapshotEffectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma
inferredcites →https://doi.org/10.1016/j.cmi.2017.02.001openalex-snapshotComparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study
inferredcites →https://doi.org/10.1016/j.ijid.2014.09.004openalex-snapshotComparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study
inferredcites →https://doi.org/10.1097/md.0000000000013983openalex-snapshotComparison of the long-term efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naïve HBeAg-positive patients with chronic hepatitis B
inferredcites →https://doi.org/10.1111/apt.12344openalex-snapshotMeta‐analysis: the impact of oral anti‐viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B
inferredcites →https://doi.org/10.1111/hepr.13194openalex-snapshotRemaining hepatocellular carcinoma risk in chronic hepatitis B patients receiving entecavir/tenofovir in South Korea
inferredcites →https://doi.org/10.1111/jvh.12971openalex-snapshotMortality, liver transplantation and hepatic complications in patients with treatment‐naïve chronic hepatitis B treated with entecavir vs tenofovir
inferredcites →https://doi.org/10.1111/liv.13682openalex-snapshotLiver diseases: A major, neglected global public health problem requiring urgent actions and large‐scale screening
inferredcites →https://doi.org/10.1136/gutjnl-2019-318947openalex-snapshotComparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis
inferredcites →https://doi.org/10.4103/sjg.sjg_49_18openalex-snapshotReal-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-naïve and experienced patients with chronic hepatitis B
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4775921openalex-extractedChronic Hepatitis B Patients Under Nucleos(t)ide Analogues Treatment with Omicron BA.5 Infection: A Retrospective Study in South China
inferred← citeshttps://doi.org/10.1002/aid2.13362openalex-snapshotEntecavir versus tenofovir disoproxil fumarate on the reduction of incidence of hepatocellular carcinoma in patients with chronic hepatitis B‐related liver cirrhosis
inferred← citeshttps://doi.org/10.1002/aid2.13391openalex-snapshotEfficacy of entecavir versus tenofovir disoproxil fumarate in preventing hepatocellular carcinoma—The jury is out
inferred← citeshttps://doi.org/10.1002/hep.32155openalex-snapshotLetter to the Editor: Is HBV genotype strongly associated with HCC risk in patients with chronic hepatitis B?
inferred← citeshttps://doi.org/10.1007/s00432-025-06082-4openalex-snapshotComparison of tenofovir versus entecavir for preventing hepatocellular carcinoma in chronic hepatitis B patients: an umbrella review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.asjsur.2023.09.057openalex-snapshotEnhanced prognosis of HCC patients undergoing radical treatments with tenofovir versus entecavir: A meta-analysis based on propensity score matching studies
inferred← citeshttps://doi.org/10.1016/j.jhep.2021.09.017openalex-snapshotMethodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments
inferred← citeshttps://doi.org/10.1016/j.jhep.2022.12.007openalex-snapshotHepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis
inferred← citeshttps://doi.org/10.1055/a-1498-2512openalex-snapshotS3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11)
inferred← citeshttps://doi.org/10.1111/apt.17438openalex-snapshotEntecavir versus tenofovir on prognosis of hepatitis B virus‐related hepatocellular carcinoma after curative hepatectomy
inferred← citeshttps://doi.org/10.1111/apt.17506openalex-snapshotReview article: Available modalities for screening and imaging diagnosis of hepatocellular carcinoma—Current gaps and challenges
inferred← citeshttps://doi.org/10.1111/apt.17712openalex-snapshotLetter: Association between aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B
inferred← citeshttps://doi.org/10.1111/jgh.15249openalex-snapshotHCC risk reduction with oral nucleos(t)ide analogues in patients with chronic hepatitis B: Not perfect, not good enough
inferred← citeshttps://doi.org/10.1111/jgh.15783openalex-snapshotLower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta‐analysis
inferred← citeshttps://doi.org/10.1111/jvh.13572openalex-snapshotEfficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response
inferred← citeshttps://doi.org/10.1155/2020/8871024openalex-snapshotRisk of Hepatocellular Carcinoma Remains High in Patients with HBV-Related Decompensated Cirrhosis and Long-Term Antiviral Therapy
inferred← citeshttps://doi.org/10.1155/2022/9567041openalex-snapshotMicrovascular Invasion in Hepatocellular Carcinoma: A Review of Its Definition, Clinical Significance, and Comprehensive Management
inferred← citeshttps://doi.org/10.1159/000512780openalex-snapshotComparison of Tenofovir and Entecavir in the Prevention of Hepatocellular Carcinoma Occurrence in Patients with Chronic Hepatitis B
inferred← citeshttps://doi.org/10.1186/s12885-022-09413-7openalex-snapshotRisk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis
inferred← citeshttps://doi.org/10.18632/aging.202573openalex-snapshotNo difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis
inferred← citeshttps://doi.org/10.20517/2394-5079.2020.138openalex-snapshotOptimize nucleot(s)ide analogues’ to prevent hepatocellular carcinoma in patients with chronic hepatitis B: a lesson from real-world evidence
inferred← citeshttps://doi.org/10.20517/2394-5079.2021.113openalex-snapshotUse of tenofovir disoproxil fumarate is associated with a lower risk of hepatocellular carcinoma than entecavir in patients with chronic hepatitis B
inferred← citeshttps://doi.org/10.20517/2394-5079.2021.144openalex-snapshotOverview of methodologies and statistical strategies in observational studies and meta-analyses on the risk of hepatocellular carcinoma in patients with chronic hepatitis B on entecavir or tenofovir therapy
inferred← citeshttps://doi.org/10.20964/2022.12.76openalex-snapshotAnalytical Detection of Hepatitis B Antiviral Drug Entecavir using Hemoglobin Modified Nitrogen-Doped Carbon Nanotube Sensor
inferred← citeshttps://doi.org/10.3350/cmh.2021.0179openalex-snapshotEntecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
inferred← citeshttps://doi.org/10.3389/fmed.2021.637126openalex-snapshotTenofovir Disoproxil Fumarate Is Superior to Entecavir in Reducing Hepatitis B Surface Antigen for Chronic Hepatitis B in China: 2-Year Comprehensive Comparative Result of a Matched Comparative Study
inferred← citeshttps://doi.org/10.3390/cancers14112617openalex-snapshotSystematic Review with Meta-Analysis: Comparison of the Risk of Hepatocellular Carcinoma in Antiviral-Naive Chronic Hepatitis B Patients Treated with Entecavir versus Tenofovir: The Devil in the Detail
inferred← citeshttps://doi.org/10.3390/cancers15112936openalex-snapshotInverse Propensity Score-Weighted Analysis of Entecavir and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B: A Large-Scale Multicenter Study
inferred← citeshttps://doi.org/10.3390/jcm11041126openalex-snapshotHepatocellular Carcinoma in Hepatitis B Virus-Infected Patients and the Role of Hepatitis B Surface Antigen (HBsAg)
inferred← citeshttps://doi.org/10.61841/rgnxfv10openalex-snapshotCOMPARATIVE EFFECTIVENESS OF ENTECAVIR VERSUS TENOFOVIR FOR PREVENTING HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CHRONIC HEPATITIS B: A COMPREHENSIVE SYSTEMATIC REVIEW
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID:
icsacinstitute.org/submit.